

Electric Cell-Signaling Energy Waves (EcST and ESI)

Table of Content

[Purpose](#)
[Description & Definitions](#)
[Criteria](#)
[Coding](#)
[Document History](#)
[References](#)
[Special Notes](#)
[Keywords](#)

Effective Date 10/2022
Next Review Date 10/2024
Coverage Policy Medical 179
Version 2

Member-specific benefits take precedence over medical policy and benefits may vary across plans. Refer to the individual's benefit plan for details [*](#).

Purpose:

This policy addresses the medical necessity of Electric Cell-Signaling Energy Waves (EcST and ESI).

Description & Definitions:

Electric cell-Signaling energy waves (EcST and ESI) is a non-surgical, non-invasive electromagnetic neuromuscular stimulation produced by an ultra-high digital frequency generator (UHdfg) that delivers signals directly into the body's cells for treatment of acute and chronic pain, long-term (intractable) pain, and drug-resistant pain.

Criteria:

Electric Cell-Signaling Energy Waves (EcST and ESI) is considered not medically necessary for any indication.

Coding:

Medically necessary with criteria:

Coding	Description
	None

Considered Not Medically Necessary:

Coding	Description
G0283	Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care.

U.S. Food and Drug Administration (FDA) - approved only products only.

Document History:

Revised Dates:

Reviewed Dates:

- 2023: October

Effective Date:

- October 2022

References:

Specialty Association Guidelines; Government Regulations; Winifred S. Hayes, Inc; UpToDate; Literature Review; Specialty Advisors; National Coverage Determination (NCD); Local Coverage Determination (LCD).

(2022). Retrieved Sep 20, 2022, from UpToDate:

https://www.uptodate.com/contents/search?search=pain%20management&sp=0&searchType=PLAIN_TEXT&source=USER_INPUT&searchControl=TOP_PULLDOWN&searchOffset=1&autoComplete=true&language=en&max=10&index=0~10&autoCompleteTerm=pain%20man

(2022). Retrieved Sep 20, 2022, from National Comprehensive Cancer Network: <https://www.nccn.org/search-result?indexCatalogue=nccn-search-index&searchQuery=Electric%20cell-Signaling%20treatment&wordsMode=AllWords>

(2022, May 18). Retrieved Sep 21, 2022, from MCG: <https://careweb.careguidelines.com/ed26/index.html>

(2022). Retrieved Sep 21, 2022, from DynaMed:

<https://www.dynamedex.com/results?q=electroanalgesia&lang=en>

(2022). Retrieved Sep 21, 2022, from Google, Inc:

https://www.google.com/search?q=Clinical+guidelines+for+RST+Treatment+%28sanexcis%29+neoGEN%C2%A&safe=strict&rlz=1C1GCEA_enUS982US982&sxsrf=ALiCzsajWFXpdUqXJz77MMQn0q6jbIKKIQ%3A1663764427654&ei=ywcrY-qjJ8erqtsPzdS4oA8&ved=0ahUKEwiqtcy99aX6AhXHIWoFHU0qDvQ

LCA: Billing and Coding: Nerve Blocks and Electrostimulation for Peripheral Neuropathy. (2022, Oct 01).

Retrieved Sep 20, 2022, from Centers for Medicare and Medicaid Services: <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=56731&ver=10>

LCD: Nerve Blocks and Electrostimulation for Peripheral Neuropathy (L37642). (2021, Jul 29). Retrieved Sep 20,

2022, from Centers for Medicare and Medicaid Services: [https://www.cms.gov/medicare-coverage-](https://www.cms.gov/medicare-coverage-database/search-)

[results.aspx?keyword=iontophoresis&keywordType=starts&areald=s53&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all](https://www.cms.gov/medicare-coverage-database/search-results.aspx?keyword=iontophoresis&keywordType=starts&areald=s53&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all)

Musculoskeletal Program - Appropriate Use Criteria: Interventional Pain Management. (2022, Mar 13). Retrieved

Sep 20, 2022, from AIM Specialty Health: [https://aimspecialtyhealth.com/wp-](https://aimspecialtyhealth.com/wp-content/uploads/2021/12/Interventional-Pain-Management-03-13-22.pdf)

[content/uploads/2021/12/Interventional-Pain-Management-03-13-22.pdf](https://aimspecialtyhealth.com/wp-content/uploads/2021/12/Interventional-Pain-Management-03-13-22.pdf)

neoGEN® system. (2022). Retrieved Sep 20, 2022, from RST SANEXAS: <https://www.rstsanexas.com/neogen/>

NEOGENESYS 2K. (2003, Jan 24). Retrieved Sep 20, 2022, from Food and Drug Administration:

<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K022433>

neoGEN-Series System (RST-Sanexas, Inc.) for Treatment of Neuropathic Pain. (2021, Mar 24). Retrieved Sep 20, 2022, from Hayes, Inc: <https://evidence.hayesinc.com/report/earb.neogenpain4906>

Rehabilitation Manual - Chapter 4: Covered Services and Limitations (Rehab). (2022, Aug 15). Retrieved Sep 21, 2022, from Department of Medical Assistance Services: https://vamedicaid.dmas.virginia.gov/manual-chapters/covered-services-and-limitations-rehab?manual_id=18101

Special Notes: *

Medical policies can be highly technical and complex and are provided here for informational purposes. These medical policies are intended for use by health care professionals. The medical policies do not constitute medical advice or medical care. Treating health care professionals are solely responsible for diagnosis, treatment, and medical advice. Sentara Health Plan members should discuss the information in the medical policies with their treating health care professionals. Medical technology is constantly evolving, and these medical policies are subject to change without notice, although Sentara Health Plan will notify providers as required in advance of changes that could have a negative impact on benefits.

Services mean both medical and behavioral health (mental health) services and supplies unless We specifically tell You otherwise. We do not cover any services that are not listed in the Covered Services section unless required to be covered under state or federal laws and regulations. We do not cover any services that are not Medically Necessary. We sometimes give examples of specific services that are not covered but that does not mean that other similar services are covered. Some services are covered only if We authorize them. When We say You or Your We mean You and any of Your family members covered under the Plan. Call Member Services if You have questions.

Keywords:

SHP Electric Cell-Signaling Energy Waves, EcST, ESI, SHP Medical 179, NeoGen, circulatory issues, acute pain, chronic pain, long-term (intractable) pain, drug-resistant pain. Electric cell-Signaling treatment, EcST, electronic signal energy waves, ultra-high digital frequency generator, UHdfg, SANEXAS neoGEN, interferential current therapy (IFT), Electroanalgesia